Clinical Treatment
Eisai Completes Submission to US FDA for LEQEMBI Application for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Eisai
PR-10-24-NI-70Nov 01, 2024
Agreement
Eisai and Empatica Enter an Agreement to Co-Promote the Embrace2 Device for People Living With Epilepsy in the U.S.
Eisai
PR-M02-19-NI-048Feb 21, 2019
Phase III
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study: Advances in Sleep and Circadian Science
Eisai
PR-M02-19-NI-010Feb 06, 2019
Pediatric
Eisai Announces FDA Approval Of FYCOMPA® in Pediatric Patients As Young As 4 Years Old For The Treatment Of Partial-Onset Seizures
Eisai
PR-M10-18-NI-022-3589Oct 05, 2018